- Home
- AEVA vs CRVS Comparison
AEVA vs CRVS Comparison
Compare AEVA & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- CRVS
- Stock Information
- Founded
- AEVA 2019
- CRVS 2014
- Country
- AEVA United States
- CRVS United States
- Employees
- AEVA N/A
- CRVS N/A
- Industry
- AEVA Auto Parts:O.E.M.
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- AEVA Consumer Discretionary
- CRVS Health Care
- Exchange
- AEVA Nasdaq
- CRVS Nasdaq
- Market Cap
- AEVA 2.0B
- CRVS 305.4M
- IPO Year
- AEVA N/A
- CRVS 2016
- Fundamental
- Price
- AEVA $26.57
- CRVS $4.17
- Analyst Decision
- AEVA Buy
- CRVS Strong Buy
- Analyst Count
- AEVA 6
- CRVS 4
- Target Price
- AEVA $16.20
- CRVS $15.00
- AVG Volume (30 Days)
- AEVA 3.4M
- CRVS 1.0M
- Earning Date
- AEVA 08-06-2025
- CRVS 08-05-2025
- Dividend Yield
- AEVA N/A
- CRVS N/A
- EPS Growth
- AEVA N/A
- CRVS N/A
- EPS
- AEVA N/A
- CRVS N/A
- Revenue
- AEVA $10,326,000.00
- CRVS N/A
- Revenue This Year
- AEVA $94.59
- CRVS N/A
- Revenue Next Year
- AEVA $165.22
- CRVS N/A
- P/E Ratio
- AEVA N/A
- CRVS N/A
- Revenue Growth
- AEVA 95.90
- CRVS N/A
- 52 Week Low
- AEVA $2.36
- CRVS $1.96
- 52 Week High
- AEVA $38.80
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- AEVA 51.76
- CRVS 53.38
- Support Level
- AEVA $25.26
- CRVS $4.08
- Resistance Level
- AEVA $34.48
- CRVS $4.31
- Average True Range (ATR)
- AEVA 3.76
- CRVS 0.25
- MACD
- AEVA -1.13
- CRVS 0.01
- Stochastic Oscillator
- AEVA 19.53
- CRVS 68.66
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).